1-2 of 2
Jörg Chromik, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Combination of AXL Inhibitor Bemcentinib and Low Dose Cytarabine Is Well Tolerated and Efficacious in Elderly Relapsed AML Patients: Update from the Ongoing BGBC003 Phase II Trial (NCT02488408)

Sonja Loges, MD PhD, Michael Heuser, Jörg Chromik, MD, Carlos Enrique Vigil, MD, Peter Paschka, MD, Francesca Re, MD, Nicola Di Renzo, MD, Roberto M. Lemoli, Daniele Giovanni Mattei, MD, Isabel Ben-Batalla, PhD, Monica Hellesoy, PhD, Katherine Lorens, MD, Joseph Birkett, PhD, Stuart McPherson, BSc, Jaya Nautiyal, PhD, David Micklem, PhD, Hani Gabra, MD PhD FRCPE, FRCP, James B. Lorens, PhD, Walter Fiedler, MD, Yesid Alvarado, MD, Bjorn T. Gjertsen, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 14.
https://doi.org/10.1182/blood-2020-136566
Published: 2020
Journal Articles

Durable Responses Observed in Elderly AML Patients Unfit for Intensive Chemotherapy with First-in Class Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with LDAC: Phase II Open-Label Study

Sonja Loges, MD, PhD, Michael Heuser, MD, Jörg Chromik, MD, Carlos Enrique Vigil, MD, Peter Paschka, MD, Francesca Re, Nicola Di Renzo, MD, Roberto Massimo Lemoli, MD, Daniele Giovanni Mattei, MD, Isabel Ben Batalla, PhD, Monica Hellesoy, PhD, David Micklem, PhD, Robert J. Holt, PhD, James B. Lorens, PhD, Muhammad Shoaib, MD, Hassan Aly, MD PhD, Wouter Hanekom, MD, Walter Fiedler, MD, Jorge E. Cortes, MD, Bjorn T. Gjertsen, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3943.
https://doi.org/10.1182/blood-2019-128683
Published: 2019